Prusogliptin

Prusogliptin
Clinical data
Other names	DBPR108
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S,4S)-4-Fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile;
CAS Number	1186426-66-3;
PubChem CID	44201003;
ChemSpider	24662486;
UNII	E329HG23ZT;
ChEMBL	ChEMBL1082462;
Chemical and physical data
Formula	C16H25FN4O2
Molar mass	324.400 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F;
	InChI InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1; Key:VQKSCYBKUIDZEI-STQMWFEESA-N;

Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.^[1]^[2]^[3]

Other namesDBPR108

Quick facts Clinical data, Other names ...

Close

References